Today, millions of people across the globe suffer from allergies, asthma, and other related immunologic disease. Though clinical practice of sublingual immunotherapy in the United States dates back nearly 100 years, research validating what was learned clinically has only begun to garner attention in the past few decades.
A large number of controlled clinical trials in Europe have shown the effectiveness of sublingual immunotherapy in the treatment of allergic rhinitis and asthma for single antigens. More studies are underway in the United States and globally today, including studies that have explored food allergies. Additional research has shed light on the mechanisms behind sublingual immunotherapy, notably the unique role dendritic cells under the tongue play in building tolerance.
A number of modern research references for sublingual immunotherapy, including recent findings through the Agency for Healthcare Research & Quality (AHRQ) can be found in our Bibliography; studies that specifically address the key tenets of the La Crosse Method can be found in our Supporting Evidence section, and we will continue to share information on new research in Ongoing Studies.